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Risk Stratification for Bleeding Complications in Patients With Venous
Thromboembolism: Application of the HAS-BLED Bleeding Score
During the First 6 Months of Anticoagulant Treatment
Joshua D. Brown, PharmD, PhD; Amie J. Goodin, PhD, MPP; Gregory Y. H. Lip, MD, FRCP, DFM, FACC, FESC; Val R. Adams, PharmD, BCOP
Background-—The Hypertension, Abnormal renal/liver function, Stroke, Bleeding, Labile International Normalized Ratio (INR),
Elderly, Drugs or alcohol use (HAS-BLED) score has strong predictive validity for major bleeding complications, but limited
validation has been conducted in venous thromboembolism (VTE). This study evaluates the HAS-BLED score in a large cohort of
VTE patients.
Methods and Results-—A retrospective cohort of adults ≥18 years with primary diagnosis of VTE between January 1, 2010 and
November 31, 2013 were identified in an insurance claims database. Patients were tracked until death, any bleed event, or end of
study period. HAS-BLED score and components were evaluated via proportional hazard models. Cumulative incidence functions
were reported at 30, 60, 90, and 180 days. N=132 280 patients with a VTE were identified, with 73.8% having HAS-BLED scores of
0 to 2, 3.6% score ≥4, and 4789 bleeding events (3.6% all patients). A 1-point HAS-BLED score increase was associated with 20% to
30% bleeding rate increase overall, but in a cancer cohort only the increase from 3- to 4-points was significant for all bleeds
(csHR=1.41, 95% CI: 1.17–1.69; sdHR=1.40, 95% CI: 1.17–1.69) and major bleeds (csHR=1.66, 95% CI: 1.26–2.20; sdHR=1.66,
95% CI: 1.25–2.19). Adding cancer to the model as an independent covariate provided the strongest association among all
covariates, with csHR=2.25 (95% CI: 1.98–2.56) and sdHR=2.11 (95% CI: 1.85–2.41) in the model for major bleeds.
Conclusions-—The HAS-BLED score has good predictive validity for bleeding risks in patients with VTE. The addition of cancer as an
independent bleeding risk factor merits consideration, possibly as part of the “B” criterion (“bleeding tendency or predisposition”).
( J Am Heart Assoc. 2018;7:e007901. DOI: 10.1161/JAHA.117.007901.)
Key Words: HAS-BLED score • risk stratification • venous thromboembolism
V enous thromboembolism (VTE), including both deep veinthrombosis and pulmonary embolism affects around 1 to
2 adults per 1000 every year.1 The most recent American
College of Chest Physicians (ACCP) guidelines recommend
treatment with non-vitamin K antagonist oral anticoagulants
over vitamin K antagonists (eg, warfarin) in patients without
cancer for at least 3 months.2 In patients with cancer, low-
molecular weight heparins (LMWH) are recommended over
other treatments. The goal of anticoagulation is to treat the
current VTE and to prevent recurrent VTE. However, antico-
agulation also imposes an increased risk for bleeding events
and this risk must be assessed to determine appropriateness
of a given treatment plan for each patient.
In an analogous treatment paradigm, individuals with atrial
fibrillation (AF) often receive long-term anticoagulation for
prevention of cerebrovascular events. In the AF population,
risk scores are now commonly used as clinical decision
support tools to initiate anticoagulation based on stroke risk
(eg, CHADSs and CHA2DS2-VASc).
3 More recently, bleeding
risk scores have been developed to go hand-in-hand with
stroke risk scores to determine the potential net clinical
benefit of anticoagulation and to guide patient follow-up
throughout therapy.3
The Hypertension, Abnormal renal/liver function, Stroke,
Bleeding, Labile International Normalized Ratio (INR), Elderly,
Drugs or alcohol use (HAS-BLED) score is one such score and
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has been shown to have strong predictive validity for major
bleeding complications.4 HAS-BLED has been validated across
several AF cohorts4,5 and has recently been applied to
patients with VTE to determine its ability to identify those at
the highest risk.6 These prior studies of VTE cohorts have
been limited in size and number of events, and have thus been
unable to establish a clear ability of the HAS-BLED score to
assess bleeding risk in a VTE population.
This study’s primary objective was to evaluate the HAS-
BLED score in a large cohort of VTE patients receiving
outpatient anticoagulation treatment. Second, the HAS-BLED
score was evaluated in a subgroup of VTE patients with
cancer. The latter objective fulfills a crucial gap in the
literature, given that cancer is one of the strongest risk
factors for VTE and presents a more complicated patient
population in regards to additional risk factors for adverse
bleeding events.
Methods
This retrospective cohort study used the Truven Health
MarketScan Commercial Claims and Medicare Supplemental
Databases from the years 2010–2014. The MarketScan data
include 40 million individuals from >160 large employers
and health plans across the United States. The data represent
an individual’s healthcare utilization including medical claims
with diagnosis and procedure codes for medical encounters
and all prescription medication fills, as well as in-hospital
mortality. These data are de-identified in compliance with the
Health Insurance Portability and Accountability Act regulations
(HIPAA) and the University of Kentucky Institutional Review
Board approved the use of the database for this study. The data
are licensed and are not available for public dissemination.
Codes for analytic methods are available from the authors on
request for purposes of reproducing the study results.
Cohort Selection
Adults aged ≥18 years diagnosed with a VTE event between
January 1, 2010 and November 31, 2013 were identified. The
date of the first qualifying diagnosis of VTE was defined as the
index date, requiring that the diagnosis was in the primary
position on an inpatient hospital record. VTE was identified by
International Classification of Disease, 9th revision (ICD-9)
codes based on previously validated coding algorithms.7
Patients were further required to have at least 12 months of
pre-index and a 1-month minimum of post-index continuous
enrollment with medical and outpatient pharmacy information
included in the database. Patients were also required to be
treatment-na€ıve (ie, no anticoagulant therapy during the
baseline period), to present an anticoagulant treatment na€ıve
cohort.
Cohort Characteristics
The cohort was described by age (18–64, 65–74, ≥75 years)
and sex. All categories for the HAS-BLED score were identified
by ICD-9 codes including: hypertension, liver disease, history
of stroke, history of bleeding,8 alcohol abuse, and drug
abuse.9 NSAIDs or antiplatelet medications were identified
from pharmacy records. The “labile INR” criterion of HAS-
BLED was not assessed given that the cohort was required to
be anticoagulant treatment-na€ıve and no such records would
exist.
Patients were assigned a total HAS-BLED score of 1-point
each for hypertension, renal disease, liver disease, history of
stroke, history of bleeding, aged >65 years, medication use
predisposing to bleeding (NSAIDs and antiplatelets), and
alcohol and/or drug abuse. Patients with malignant neo-
plasms and/or metastatic disease during the baseline period
were also identified using ICD-9 codes 140.x to 209.x.
Anticoagulant treatment was identified as the first observed
LMWH, non-vitamin K antagonist oral anticoagulant, or
warfarin, allowing for bridge therapy from LMWH to warfarin.
Patient Follow-Up and Outcomes
All bleeding events were tracked during the 180 days
following the initial VTE diagnosis. Patients were followed up
until they experienced a bleeding event, were censored due to
Clinical Perspective
What Is New?
• The HAS-BLED score has been widely used for risk
stratification in patients with atrial fibrillation receiving
anticoagulation.
• This study shows that HAS-BLED has high predictive validity
for bleeding events in venous thromboembolism (VTE)
patients receiving anticoagulation.
• Further, we show that cancer is a strong independent risk
factor for bleeding in this population and should be included
in the risk score.
What Are the Clinical Implications?
• HAS-BLED can be used in patients with VTE to predict the
risk of a bleeding event while being anticoagulated.
• Bleed risk stratification scores should not be used to
withhold treatment.
• Rather, risk scores can be used to identify patients for
monitoring or modified therapeutic approaches as well as
identification of some modifiable risk factors (eg, blood
pressure, medication use).
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dropping out of the database, they died, or until the end of the
study period or follow-up time. Bleeding events were classified
as “all” if they met the coding algorithm used or “major” if
they occurred during an inpatient stay, were associated with a
critical site, resulted in need for transfusion, or lead to death
while in the hospital.10
Statistical Analysis
A time-to-event, survival analytic approach was taken. Given
that there is a high risk of death in the overall cohort, and an
especially elevated risk in the cancer sub-group, it was
deemed necessary to assess outcomes in a competing risks
framework, taking death into account as a competing event to
the primary bleeding outcome.11
The cumulative incidence function (CIF) of all bleeding
events and major bleeding events were modeled using Fine
and Gray’s method for competing risks which reported the
incidence proportion at multiple time periods (30, 60, 90,
180 days).12 CIF plots were stratified by HAS-BLED scores
and show the incidence of bleeding complications, taking into
account both censoring and competing events during follow-
up. Gray’s statistical tests for the equality of CIF curves
between HAS-BLED stratifications were conducted.
Table 1. Demographic and Clinical Characteristics of Patients With an Index Venous Thromboembolism
DVT Only PE With or Without DVT Overall
N % N % N %
Total 60 930 46.1 71 350 53.9 132 280 100
Age, y
18 to 64 36 731 60.3 47 520 66.6 84 251 63.7
65 to 74 7793 12.8 8978 12.6 16 771 12.7
≥75 16 406 26.9 14 852 20.8 31 258 23.6
Sex (male) 27 734 52.0 32 257 51.5 59 991 45.4
Hypertension 28 682 53.8 30 127 48.1 58 809 44.5
Renal disease 6365 11.9 3770 6.0 10 135 7.7
Liver disease 3826 7.2 3733 6.0 7559 5.7
History of stroke 6943 13.0 5470 8.7 12 413 9.4
History of bleeding 8076 15.2 7405 11.8 15 481 11.7
Medication use (NSAIDs, antiplatelets) 16 443 30.8 19 908 31.8 36 351 27.5
Alcohol or drug use 827 1.6 843 1.4 1670 1.3
Cancer 12 586 23.6 12 329 19.7 24 915 18.8
Metastatic cancer 4197 7.9 4317 6.9 8514 6.4
HAS-BLED Score
0 12 564 23.6 18 023 28.8 30 587 23.1
1 16 424 30.8 20 858 33.3 37 282 28.2
2 14 536 27.3 15 282 24.4 29 818 22.5
3 7048 13.2 6389 10.2 13 437 10.2
4 2320 4.4 1786 2.9 4106 3.1
5 397 0.7 251 0.4 648 0.5
6 28 0.1 19 0.0 47 0.0
7 2 0.0   2 0.0
Anticoagulation
LMWH 5955 11.2 3980 6.4 9935 7.5
NOAC 8465 15.9 12 100 19.3 20 565 15.5
Warfarin 38 899 73.0 46 528 74.3 85 427 64.6
DVT indicates deep vein thrombosis; HAS-BLED, Hypertension, Abnormal renal/liver function, Stroke, Bleeding, Labile International Normalized Ratio (INR), Elderly, Drugs or alcohol use;
LMWH, low molecular weight heparin; NOAC, non-vitamin K antagonist oral anticoagulant; PE, pulmonary embolism.
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Two proportional hazard regression models specifications
were used. A cause-specific model was used which treats the
competing risk as a censoring event. This models the
instantaneous rate of bleeding events among subjects who
are event free at a given time point (no bleeding, no death).
The cause-specific model is comparable to a typical Cox
proportional hazard model. A sub-distribution model was also
used which accounts directly for death as a competing risk by
retaining those that die within a given time point in the risk
set. Such a model provides an estimate of the instantaneous
rate of bleeding events in those who have not experienced a
bleed or have died within the time interval. Including both
models allowed for broader interpretation of results as each
has unique implications and applications.11 Specifically, using
both approaches allows for an assessment of how the risk of
death interplays with the risk of bleeding and the association
of each with the included covariates.
From each model, cause-specific (csHR) and sub-distribu-
tion (sdHR) hazard ratios and 95% confidence intervals (CI) are
reported for the HAS-BLED score, individual components of
the HAS-BLED score, and for cancer. To better compare HAS-
BLED scores and potential low/high risk cut-offs, hazard
Table 2. Cumulative Incidence Proportion of Bleeding Events at 30, 60, 90, and 180 Days of Follow-Up by HAS-BLED Score
Time to Bleeding Event
HAS-BLED Score
0 1 2 3 ≥4
(A) Major bleeds, overall
30 d 0.5% (0.4–0.5%) 0.5% (0.5–0.6%) 0.6% (0.5–0.7%) 0.6% (0.5–0.8%) 1.1% (0.9–1.4%)
60 d 0.6% (0.5–0.7%) 0.7% (0.6–0.8%) 0.8% (0.8–0.9%) 0.8% (0.7–1.0%) 1.7% (1.4–2.0%)
90 d 0.7% (0.6–0.8%) 0.9% (0.8–1.0%) 1.1% (1.0–1.2%) 1.1% (1.0–1.3%) 2.3% (2.0–2.7%)
180 d 0.9% (0.8–1.1%) 1.3% (1.1–1.4%) 1.7% (1.5–1.8%) 2.0% (1.8–2.3%) 3.4% (3.0–3.9%)
(B) Major bleeds, no cancer
30 d 0.4% (0.3–0.5%) 0.5% (0.4–0.5%) 0.5% (0.4–0.6%) 0.6% (0.5–0.8%) 1.0% (0.7–1.3%)
60 d 0.5% (0.4–0.6%) 0.6% (0.5–0.7%) 0.7% (0.6–0.8%) 0.8% (0.6–0.9%) 1.5% (1.2–1.9%)
90 d 0.6% (0.5–0.7%) 0.8% (0.7–0.9%) 0.9% (0.8–1.0%) 1.0% (0.9–1.2%) 2.1% (1.7–2.6%)
180 d 0.7% (0.6–0.8%) 1.0% (0.9–1.2%) 1.3% (1.2–1.5%) 1.8% (1.6–2.1%) 3.1% (2.6–3.7%)
(C) Major bleeds, cancer only
30 d 0.9% (0.7–1.3%) 0.7% (0.6–0.9%) 0.9% (0.7–1.1%) 0.7% (0.5–0.9%) 1.3% (0.9–1.9%)
60 d 1.3% (1.0–1.7%) 1.1% (0.8–1.3%) 1.3% (1.1–1.6%) 1.0% (0.8–1.3%) 1.9% (1.4–2.6%)
90 d 1.7% (1.3–2.1%) 1.3% (1.1–1.6%) 1.7% (1.5–2.0%) 1.3% (1.1–1.7%) 2.7% (2.1–3.4%)
180 d 2.4% (1.9–2.9%) 2.1% (1.8–2.5%) 2.6% (2.2–2.9%) 2.5% (2.1–3.0%) 4.1% (3.3–5.0%)
(D) All bleeds, overall
30 d 1.2% (1.1–1.4%) 1.4% (1.3–1.5%) 1.5% (1.4–1.6%) 1.5% (1.4–1.7%) 2.5% (2.2–2.9%)
60 d 1.6% (1.5–1.8%) 1.9% (1.8–2.1%) 2.1% (1.9–2.2%) 2.2% (2.0–2.4%) 3.7% (3.2–4.2%)
90 d 1.9% (1.8–2.1%) 2.4% (2.2–2.5%) 2.7% (2.6–2.9%) 3.1% (2.8–3.3%) 5.0% (4.5–5.6%)
180 d 2.6% (2.4–2.8%) 3.4% (3.2–3.6%) 4.2% (4.0–4.4%) 5.3% (4.9–5.6%) 8.0% (7.3–8.7%)
(E) All bleeds, no cancer
30 d 1.0% (0.9–1.2%) 1.3% (1.1–1.4%) 1.3% (1.2–1.5%) 1.6% (1.4–1.8%) 2.3% (1.9–2.8%)
60 d 1.4% (1.2–1.5%) 1.7% (1.6–1.9%) 1.8% (1.7–2.0%) 2.1% (1.9–2.4%) 3.5% (3.0–4.1%)
90 d 1.6% (1.4–1.8%) 2.1% (1.9–2.2%) 2.3% (2.1–2.5%) 2.9% (2.6–3.2%) 4.8% (4.2–5.5%)
180 d 2.1% (2.0–2.3%) 2.9% (2.7–3.1%) 3.6% (3.4–3.9%) 4.8% (4.4–5.2%) 7.6% (6.8–8.5%)
(F) All bleeds, cancer only
30 d 2.5% (2.0–3.0%) 1.9% (1.6–2.2%) 1.9% (1.6–2.1%) 1.4% (1.2–1.8%) 2.9% (2.2–3.6%)
60 d 3.3% (2.7–3.8%) 2.8% (2.4–3.1%) 2.8% (2.5–3.2%) 2.4% (2.1–2.9%) 4.1% (3.3–4.9%)
90 d 4.2% (3.6–4.9%) 3.5% (3.1–3.9%) 3.8% (3.4–4.2%) 3.5% (3.0–4.0%) 5.4% (4.5–6.4%)
180 d 5.9% (5.2–6.7%) 5.4% (4.9–6.0%) 5.8% (5.4–6.3%) 6.3% (5.6–7.0%) 8.6% (7.4–9.9%)
HAS-BLED indicates Hypertension, Abnormal renal/liver function, Stroke, Bleeding, Labile International Normalized Ratio (INR), Elderly, Drugs or alcohol use.
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ratios are presented incrementally (ie, comparing the level
with the previous level, rather than having a common
reference group). Anticoagulant treatment was included as a
covariate to control for any selection bias in treatment
selection. C-indices, a metric of model concordance or, the
ability of the model to identify those who will have outcomes,
are reported.
All data analysis was performed using SAS Enterprise
Guide (SAS Institute, Cary, NC) version 7.1 with an a priori
alpha of 0.05 for statistical significance.
Results
Over the study period, N=132 280 patients with VTE were
identified including 60 930 (46.1%) with deep vein thrombosis
and 71 350 (53.9%) with pulmonary embolism (Table 1).
Nearly two-thirds were aged 18 to 64 years (63.7%), and
45.4% were male. The most common HAS-BLED component
was hypertension (44.5%), followed by NSAID or antiplatelet
medication use (27.5%), cancer (18.8%), and a history of
bleeding (11.7%). The large majority of patients had HAS-BLED
scores of 0 to 2, 10.2% had a score of 3, and 3.6% had a score
≥4. The majority of patients received warfarin (64.6%), 15.5%
received non-vitamin K antagonist oral anticoagulants, and
7.5% received LMWH. Treatment did not differ based on the
HAS-BLED score in the overall cohort but cancer patients
were more likely to receive LMWH than non-cancer patients,
which is consistent with US treatment guidelines.2,13
There were a total of 4789 (3.6% of all patients) bleeding
events of which, 1847 (38.6%) were classified as major
bleeds. Median time to bleed was 50 days (mean 62 days) for
all bleeds as well as major bleeds. An additional 2739 patients
(2.1% of all patients) died in the hospital during follow-up with
a median time to death of 66 days after index. The remainder
of patients were censored with mean follow-up of 16032
days.
Table 2 shows the 30, 60, 90, and 180-day CIF estimates
of all bleeds and major bleeds stratified by the HAS-BLED
scores with the corresponding CIF plots in Figure. The
incidence of bleeding events increased with increasing HAS-
BLED scores with statistically significant differences between
HAS-BLED scores (P<0.001). Directly comparing the HAS-
BLED scores of 3 and 4, which have been investigated
previously as cut points for distinguishing high risk, at 180-
days a score of 4 had cumulative incidence for major bleeding
of 3.1% (2.7–3.6%) and all bleeding of 7.3% (6.6–8.0%). A HAS-
BLED score of 3 was associated with a cumulative incidence
of 5.3% (4.9–5.6%), which was significantly lower than the
HAS-BLED ≥4 group (P<0.001). The cancer cohort had a
higher risk of bleeding than the overall and non-cancer cohort
and there was a consistent correlation between increases in
HAS-BLED scores and the risk of bleeding events.
Figure. Cumulative incidence function plots of major (A through C) and all (D through F) bleeding events stratified by HAS-BLED scores for
overall (A and D), non-cancer (B and E), and cancer groups (C and F). HAS-BLED indicates Hypertension, Abnormal renal/liver function,
Stroke, Bleeding, Labile International Normalized Ratio (INR), Elderly, Drugs or alcohol use. Graph lablel of HAS-BLED score of “4” indicates
HAS-BLED ≥ 4.
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The results of the regression analyses are provided in
Table 3 for the HAS-BLED score and Table 4 for individual
components and cancer variables. Overall, an increase of 1
point in the HAS-BLED score increased the rate of bleeding by
20% to 30%. In the cancer only cohort, increases from 0
points to 3 points were not statistically significant. For cancer,
only increasing from 3 points to 4 points total was significant.
In Table 4, most of the HAS-BLED’s individual components
were significant predictors of major and all bleeding with
hazard ratios ranging from 1.35 to 1.90. Age and high bleed
risk medication use were not found to be significantly
predictive in these results.
Adding cancer to the model as an independent covariate
provided the strongest association of all included covariates,
with hazard ratios of 2.25 (95% CI: 1.98–2.56) in the cause-
specific model for major bleeds and 2.11 (95% CI: 1.85–2.41)
in the sub-distribution model for major bleeds. Similar results
were observed for all bleeds, with hazard ratios of 2.07 (95%
CI: 1.91–2.25) in the cause-specific model and 1.94 (95% CI:
1.78–2.11) in the sub-distribution model. C-indices ranged
between 0.66 to 0.73 and were highest for the non-cancer
cohort versus the cancer cohort.
Discussion
To our knowledge this is the largest and most comprehensive
analysis using the HAS-BLED score to assess bleeding in
patients with VTE. Our principal findings are that the HAS-
BLED score has good predictive validity for bleeding risks in
patients with VTE, where a HAS-BLED score of ≥4 indicated a
clear delineation for those at high risk for major bleeding
among the total cohort. This observation remained consistent
when comparing risk for major bleeding among cancer and
non-cancer patients. Second, the addition of cancer as an
independent risk factor to bleeding risk merits consideration,
possibly as part of the B criterion (“bleeding tendency or
predisposition”) of the HAS-BLED score.
The use of theHAS-BLED score, or any risk stratification tool,
in patients with VTE should be appropriately applied and not
misused.14 A designation of “high risk” in this population should
be used to “flag up” high risk patients for additional review and
follow-up. More importantly, the management of reversible
bleeding risk factors (and the HAS-BLED score containsmost of
the more common modifiable bleeding risk factors) should be
performed in all patients, and the designation of high bleed risk
is not intended for the withholding of anticoagulation therapy in
many patients with VTE.
The HAS-BLED score has been most validated in patients
with AF, where it was predictive of bleeding in patients on no
antithrombotic therapy, aspirin and anticoagulants (whether
warfarin or non-warfarin anticoagulants).4,15 Data in VTE
patients are more limited. For example, Kooiman, et al found
an increased risk of major bleeding at a HAS-BLED score of
≥3 in a cohort of 537 acute VTE patients.6 The present study
greatly extends the work by Kooiman et al by replicating the
study design using a substantially larger cohort, where
Table 3. Survival Regression Model Showing the Incremental
Cause-Specific and Sub-Distribution Hazard Ratios Comparing
HAS-BLED Scores Risk of Bleeding Events
HAS-BLED Score
Comparison
Cox PH Competing Risks
csHR 95% CI sdHR 95% CI
(A) Major bleeds, overall
HAS-BLED 1 vs 0 1.34 1.15 to 1.56 1.34 1.15 to 1.55
HAS-BLED 2 vs 1 1.31 1.16 to 1.49 1.31 1.16 to 1.48
HAS-BLED 3 vs 2 1.22 1.06 to 1.39 1.21 1.06 to 1.39
HAS-BLED ≥4 vs 3 1.71 1.44 to 2.04 1.71 1.44 to 2.03
(B) Major bleeds, no cancer
HAS-BLED 1 vs 0 1.44 1.20 to 1.73 1.44 1.20 to 1.72
HAS-BLED 2 vs 1 1.26 1.08 to 1.47 1.26 1.08 to 1.47
HAS-BLED 3 vs 2 1.37 1.16 to 1.63 1.37 1.15 to 1.63
HAS-BLED ≥4 vs 3 1.72 1.38 to 2.14 1.71 1.38 to 2.14
(C) Major bleeds, cancer only
HAS-BLED 1 vs 0 0.88 0.67 to 1.14 0.89 0.68 to 1.15
HAS-BLED 2 vs 1 1.22 0.99 to 1.49 1.23 1.00 to 1.50
HAS-BLED 3 vs 2 0.95 0.77 to 1.19 0.95 0.77 to 1.19
HAS-BLED ≥4 vs 3 1.66 1.26 to 2.20 1.66 1.25 to 2.19
(D) All bleeds, overall
HAS-BLED 1 vs 0 1.29 1.18 to 1.41 1.28 1.17 to 1.41
HAS-BLED 2 vs 1 1.24 1.15 to 1.33 1.24 1.14 to 1.33
HAS-BLED 3 vs 2 1.24 1.14 to 1.35 1.24 1.14 to 1.35
HAS-BLED ≥4 vs 3 1.55 1.38 to 1.73 1.54 1.38 to 1.73
(E) All bleeds, no cancer
HAS-BLED 1 vs 0 1.35 1.21 to 1.50 1.34 1.21 to 1.50
HAS-BLED 2 vs 1 1.24 1.13 to 1.36 1.24 1.13 to 1.36
HAS-BLED 3 vs 2 1.33 1.20 to 1.48 1.33 1.20 to 1.48
HAS-BLED ≥4 vs 3 1.62 1.41 to 1.86 1.61 1.40 to 1.86
(F) All bleeds, cancer only
HAS-BLED 1 vs 0 0.89 0.76 to 1.05 0.90 0.76 to 1.06
HAS-BLED 2 vs 1 1.07 0.94 to 1.22 1.08 0.95 to 1.23
HAS-BLED 3 vs 2 1.05 0.92 to 1.21 1.05 0.92 to 1.21
HAS-BLED ≥4 vs 3 1.41 1.17 to 1.69 1.40 1.17 to 1.69
C-indices (95% CI) for Cox PH and competing risks models, respectively: A=0.710 (0.698
–0.723), 0.700 (0.690–0.710); B=0.730 (0.712–0.748), 0.720 (0.710–0.730); C=0.685
(0.665–0.705), 0.670 (0.658–0.682); D=0.725 (0.715–0.735), 0.715 (0.705–0.725);
E=0.735 (0.728–0.742), 0.730 (0.720–0.740); F=0.670 (0.650–0.690), 0.660 (0.635–
0.685). CI indicates confidence interval; csHR, cause-specific hazard ratio; HAS-BLED,
Hypertension, Abnormal renal/liver function, Stroke, Bleeding, Labile International
Normalized Ratio (INR), Elderly, Drugs or alcohol use; PH, proportional hazards; sdHR,
sub-distribution hazard ratio.
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estimates could be stabilized and individual elements of the
risk score could be examined.
The implications of these findings are that the current
designation of “high risk” for major bleeds may perhaps be
better attributed to those VTE patients with a HAS-BLED score
≥4 as Kooiman, et al postulated.6 As mentioned above, we
should not focus on designating a cut point for what is high risk,
but to provide further evidence for continued review or for
follow up and action to reduce the elements of the HAS-BLED
score that are modifiable (eg, alcohol excess, concomitant
NSAIDs or antiplatelets, uncontrolled hypertension, etc).14 In
the current analysis, utilizing a high-risk cut-off of HAS-BLED ≥4
would have a sensitivity of <5% for identifying true positive
cases given the distribution of the HAS-BLED scores in the
cohort studied (5% of patients had a HAS-BLED ≥4). Thus, to
prevent themost bleed events in a patient population, the range
of HAS-BLED scores should be considered, and modifiable risk
factors considered, for clinical intervention.
Cancer was included as a means to stratify the cohort
given the possible difference in baseline hazard for the cancer
population and also included as a covariate in the regression
models. Cancer is among the strongest risk factors for
VTE,16,17 and was present in roughly 20% of the cohort
studied. When included as an individual covariate along with
components of the HAS-BLED score, cancer was the strongest
predictor of major and overall bleeding. In the cancer cohort,
the HAS-BLED score without consideration of cancer
appeared to be less predictive of bleeding events compared
with the non-cancer cohort (Table 3). Along with the finding
that age and medication use were not strong predictors, a
bleeding risk score specifically tailored to a cancer population
with VTE as risk factors could inherently be different
compared with an AF population or a general VTE patient
group. Alternatively, cancer could be added as an additional
risk factor in a modified HAS-BLED score specific for patients
with VTE, where it could be part of the B criterion (“bleeding
tendency or predisposition”) of the HAS-BLED score. Further
work is needed to evaluate cancer as a risk factor for bleeding,
its suitability in a modified HAS-BLED score, and the
development of other risk scores specifically for the VTE
patient population. Of note, cancer has been included as an
independent risk factor in a recently developed, VTE-specific
bleed risk stratification score, VTE-BLEED.18
Validating an existing risk stratification tool like HAS-BLED
across multiple indications may help improve clinical adoption
and encourage its uptake in practice.19 Some urge caution in
applying bleeding risk scores in the clinical environment, due
to the development of these scores based on initial clinical
decisions to prescribe anticoagulants which necessitated that
the patients were considered lower bleed risk.20 Additionally,
bleed risk scores have only been modestly predictive of
bleeding in anticoagulated patients with VTE in a prior
validation study.21 Also, there is the perception that bleeding
risk scores are inappropriately used to deny patients antico-
agulation because of their perceived “high risk” although
bleeding risk is highly dynamic and modifiable, and the
reversible risk factors for bleeding should be addressed in all
patients rather than just those at high risk.14 HAS-BLED has
been used widely in clinical and research settings,20 and
performs better than other bleeding risk scores (including
ATRIA).19 HAS-BLED should be compared with other bleed
scores specifically developed in the VTE population18 to
determine the comparative predictive validity of these similar
clinical tools.
Table 4. Survival Regression Model Results Showing Individual HAS-BLED Components and Cancer Variables
Variable
Major Bleeds All Bleeds
Cox PH (c-Index=0.722) Competing Risks (c-Index=0.690) Cox PH (c-Index=0.710) Competing Risks (c-Index=0.685)
csHR 95% CI sdHR 95% CI csHR 95% CI sdHR 95% CI
Age 65 to 74 vs ≤64, y 0.93 0.81 to 1.07 0.94 0.82 to 1.08 0.88 0.81 to 0.97 0.89 0.82 to 0.98
Age 75+ vs ≤64, y 0.87 0.78 to 0.98 0.88 0.79 to 0.99 0.85 0.79 to 0.91 0.85 0.80 to 0.92
Hypertension 1.35 1.22 to 1.50 1.35 1.21 to 1.49 1.29 1.21 to 1.37 1.28 1.21 to 1.37
Renal disease 1.55 1.36 to 1.76 1.54 1.35 to 1.75 1.59 1.46 to 1.72 1.58 1.45 to 1.71
Liver disease 1.40 1.20 to 1.62 1.38 1.19 to 1.60 1.43 1.31 to 1.57 1.41 1.29 to 1.55
Prior stroke 1.87 1.66 to 2.10 1.86 1.65 to 2.09 1.47 1.36 to 1.59 1.46 1.36 to 1.58
Prior bleeding 1.69 1.51 to 1.88 1.69 1.51 to 1.88 1.91 1.78 to 2.04 1.91 1.78 to 2.04
High risk medication use 0.92 0.83 to 1.02 0.92 0.84 to 1.02 0.97 0.92 to 1.04 0.98 0.92 to 1.04
Alcohol/drug abuse 1.55 1.16 to 2.08 1.55 1.16 to 2.07 1.59 1.33 to 1.90 1.58 1.32 to 1.89
Cancer 2.25 1.98 to 2.56 2.11 1.85 to 2.41 2.07 1.91 to 2.25 1.94 1.78 to 2.11
CI indicates confidence interval; csHR, cause-specific hazard ratio; HAS-BLED, Hypertension, Abnormal renal/liver function, Stroke, Bleeding, Labile International Normalized Ratio (INR),
Elderly, Drugs or alcohol use; PH, proportional hazards; sdHR, sub-distribution hazard ratio.
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Limitations
There are several limitations within this study. First, admin-
istrative claims data may not reliably capture all diagnoses
and procedures within the patient population.22 Second,
previous examination of cumulative incidence in HAS-BLED
scoring of major bleed risk have not incorporated the death as
a competing risk in the cohort, which suggests that our
analysis results may not be directly comparable to previous
studies. Our measure of death included only in-hospital death
as death data are not readily available in the MarketScan
data. This will have caused an underestimation of the number
of major bleeding events detected in this study and some
misclassification of follow-up status as censored rather than
the competing risk of death. Misclassification of death is
unlikely to have impacted the magnitude of effect between
the HAS-BLED score categories given how few (2%) patients
died during follow-up. Misclassifying death would have
underestimated the effect size between higher HAS-BLED
scores versus lower scores as the lower scores likely have a
smaller proportion of in-hospital deaths and, thus, an
overestimated cumulative incidence of bleeding.11,23 Further,
there were no clear differences between Cox and competing
risks regression models which suggested little effect of
missing death data. Lastly, the database primarily contains
patients with employer-sponsored health insurance plans,
which means that lower income patients, who tend to have
worse health outcomes, are likely under-represented.
Conclusions
The HAS-BLED score has good predictive validity for bleeding
risks in patients with VTE. The addition of cancer as an
independent risk factor to bleeding risk merits consideration,
possibly as part of the B criterion (“bleeding tendency or
predisposition”) of the HAS-BLED score.
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